The April 2026 JACC: Advances synthesis of nearly eight decades of Framingham Heart Study (FHS) data marks an important milestone in recognizing that cardiovascular disease (CVD) in women is not simply a delayed version of men's disease but follows a biologically distinct and often more dangerous path. The FHS, a landmark observational prospective cohort study launched in 1948 with over 15,000 participants across six generations and minimal commercial conflicts (primarily NIH-funded), provides high-quality longitudinal evidence on risk factor impact, though it cannot prove causality like randomized controlled trials. Lead author Vanessa Xanthakis and colleagues correctly emphasize that diabetes, hypertension, and dyslipidemia confer greater relative risks in women, and that the menopause transition offers a unique window unavailable in male physiology.

Yet the MedicalXpress coverage, while accurate on surface findings, misses critical context and connections that reveal the depth of historical male bias in cardiology. It fails to integrate how reproductive milestones amplify trajectories. Meta-analyses of preeclampsia and gestational diabetes (drawing from cohorts like the Nurses' Health Study II, n>100,000) show these conditions elevate lifetime CVD risk by 2-4 times, factors rarely captured in standard male-derived risk calculators. The coverage also underplays microvascular dysfunction and heart failure with preserved ejection fraction (HFpEF), phenotypes twice as common in women according to the Women's Ischemia Syndrome Evaluation (WISE) study—an NIH-funded observational cohort of approximately 900 women—which demonstrated that ischemia without obstructive coronary arteries predicts high adverse event rates.

This pattern connects to the VIRGO study (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients, observational, n≈3,500), which found young women (<55) experiencing myocardial infarction suffer higher mortality and readmission rates than age-matched men, driven by delayed recognition of atypical symptoms and less aggressive treatment—direct legacies of decades when trials like the original lipid studies enrolled mostly men. Early Framingham interpretations and post-WWII epidemiology framed CVD as a middle-aged male epidemic, leading to the 'protected until menopause' myth that persisted despite FHS itself including women from the start. This bias delayed sex-stratified analyses until mandates like the 1993 NIH Revitalization Act, and even today women remain underrepresented in device and drug trials.

Synthesizing the 2026 FHS paper with the 2019 Lancet seminar on sex differences in CVD and the ongoing Study of Women's Health Across the Nation (SWAN, n≈3,000, observational), a clearer picture emerges: women's risk accumulates more steeply after menopause due to estrogen withdrawal affecting endothelial function, lipid profiles, and inflammation. Women also show greater sensitivity to psychosocial stressors and autoimmune contributions (female-predominant conditions like lupus double CVD risk). Plaque biology differs—women experience more plaque erosion than rupture—explaining why standard angiographic approaches miss disease.

The genuine analytical takeaway mainstream coverage has inadequately corrected is that this is not merely an equity issue but one of biological precision. Male-centric guidelines have produced suboptimal prevention, under-treatment with statins and revascularization, and worse post-event outcomes for women. Addressing it requires embedding reproductive history in all risk algorithms, mandating sex-stratified trial reporting, and developing perimenopause-specific interventions. The FHS data, while observational and thus associative, supplies the strongest long-term signal yet that ignoring sex-specific trajectories costs lives. Continued investment in mechanistic research during hormonal transitions is essential to translate these insights into equitable care.